In AML-11, AML-43, and AML-63, TP53-mutated AML was characterized by LOH, which was driven by the subfraction of leukemia initiating cells harboring both the mutation and del(17p) within a genetically heterogenous LSC pool. Here, TP53 is linked to acute myeloid leukemia.